A real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir in the treatment of genotype 1b chronic hepatitis C
10.3760/cma.j.issn.1007-3418.2018.12.010
- VernacularTitle: 奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎疗效真实世界研究
- Author:
Junping LIU
1
;
Yongqian CHENG
2
;
Jiming ZHANG
3
;
Huiming JIN
1
;
Huibin NING
1
;
Kuan LI
1
;
Mengyang MA
1
;
Yanan WU
1
;
Zhen PENG
1
;
Hui YIN
1
;
Cuiping LIU
1
;
Jia SHANG
1
Author Information
1. Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
2. The Fifth Medical Center of the General Hospital of the Chinese people's Liberation Army, BeiJing, 100039, China
3. Department of Infectious Diseases, Huashan Hospital Affiliated to Fudan University, Shanghai, 200040, China
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis C;
Therapy;
Direct acting antiviral agents;
OBV/PTV/RTV;
DSV
- From:
Chinese Journal of Hepatology
2018;26(12):927-932
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To recognize the efficacy and safety of paritaprevir/ritonavir-ombitasvir combined with dasabuvir (OBV/PTV/RTV+DSV) in the treatment of genotype 1b chronic hepatitis C.
Methods:Patients with genotype 1b chronic hepatitis C who were admitted to the People's Hospital of Henan Province, Huashan Hospital of Shanghai and the Fifth Medical Center of the General Hospital of the People's Liberation Army of China between November 2017 to August 2018 were enlisted. All patients received OBV/PTV/RTV+DSV antiviral therapy. HCV RNA levels were measured at baseline, weeks 1, 2, 3, 4, 8, 12, and 24, then 12 weeks, and 24 weeks after completion of treatment; patients’ comorbidity, concomitant medications, and clinical adverse events were recorded.
Results:108 patients were enrolled in the study, with an average age of 49.1 years, 44 patients were male (40.8%), 96.3% (104/108) were newly diagnosed, and four patients had previous treatment history, of whom three were treated with IFN and one with IFN + DAA. Ninety-eight cases completed 12 weeks treatment and 89 cases were in follow up for 12 weeks, after discontinuation of the drug. Overall, 89 cases (100%) achieved SVR12.One patient treated with PR and DAA had HCV RNA level of 869175 IU/mL at 4 weeks of treatment, which was significantly higher than the baseline HCV RNA level (301776IU/ML), and was judged as failure of treatment; and follow-up was discontinued. Of all enrolled patients, 19 (17.6%) had underlying diseases and 15 (13.9%) had combined medications. During treatment, adverse events (AE) occurred in 11 patients (10.1%). The main adverse events were pruritus and elevated bilirubin.
Conclusion:Combined antiviral therapy (OBV/PTV/RTV+DSV) of 12 weeks are highly effective with good safety profile in the treatment of Chinese patients with genotype 1b chronic hepatitis C.
